ArunA Bio, an Athens, GA-based neural exosome therapeutic platform, secured $5.3m in funding.
Backers included existing angel investors.
The company intends to use the funds to further the development of its neural exosome therapeutic platform and manufacturing processes for a broad range of neurological disorders.
Led by Steven Stice, Ph.D., co-founder, chief executive and chief scientific officer, ArunA Bio is advancing a neural exosome platform which inherently crosses the blood brain barrier and enables drugs and drug combinations to naturally target cells and treat patients with a range of neurological disorders.
Exosomes are naturally occurring biologics that can target diseased cells and facilitate their repair. They play a central role in intracellular communication, and can deliver functional proteins, mRNA transcripts, miRNA and small molecules.
They represent a promising new approach to treat a variety of diseases throughout the body.